argenx SE (ARGX.BR)
EUR 575.6
(1.34%)
EUR 575.6
(1.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.83 Billion EUR | -132.98% |
| 2022 | -788.31 Million USD | 40.42% |
| 2021 | -1.32 Billion USD | -9.36% |
| 2020 | -1.2 Billion EUR | -232.59% |
| 2019 | -363.79 Million EUR | -13.16% |
| 2018 | -321.48 Million EUR | -40.4% |
| 2017 | -228.98 Million EUR | -142.2% |
| 2016 | -94.54 Million EUR | -143.5% |
| 2015 | -38.82 Million EUR | 0.78% |
| 2014 | -39.13 Million EUR | -24.73% |
| 2013 | -31.37 Million EUR | -72.68% |
| 2012 | -18.16 Million EUR | 35.85% |
| 2011 | -28.32 Million EUR | -169.71% |
| 2010 | -10.5 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 2.94 Billion USD | 245.24% |
| 2024 Q2 | -1.4 Billion EUR | -147.66% |
| 2023 Q3 | 1.88 Billion USD | 271.83% |
| 2023 Q1 | 2.02 Billion USD | 356.41% |
| 2023 Q2 | -1.09 Billion USD | -154.39% |
| 2023 FY | -1.83 Billion EUR | -132.98% |
| 2023 Q4 | -2.02 Billion USD | -207.41% |
| 2022 Q3 | 2.65 Billion USD | 295.25% |
| 2022 FY | -788.31 Million USD | 40.42% |
| 2022 Q2 | -1.35 Billion USD | 0.0% |
| 2022 Q4 | -788.31 Million USD | -129.74% |
| 2021 Q4 | -1.32 Billion USD | 0.0% |
| 2021 FY | -1.32 Billion USD | -9.36% |
| 2021 Q2 | -1.57 Billion USD | 0.0% |
| 2020 Q4 | -1.2 Billion EUR | 0.0% |
| 2020 Q2 | -1.34 Billion EUR | 0.0% |
| 2020 FY | -1.2 Billion EUR | -232.59% |
| 2019 FY | -363.79 Million EUR | -13.16% |
| 2019 Q2 | -186.58 Million EUR | 0.0% |
| 2019 Q4 | -324.76 Million EUR | 0.0% |
| 2018 Q2 | -162.87 Million EUR | 0.0% |
| 2018 FY | -321.48 Million EUR | -40.4% |
| 2018 Q4 | -321.48 Million EUR | 0.0% |
| 2017 FY | -228.98 Million EUR | -142.2% |
| 2017 Q4 | -228.98 Million EUR | 0.0% |
| 2017 Q2 | -86.4 Million EUR | 0.0% |
| 2016 Q2 | -113.36 Million EUR | 0.0% |
| 2016 Q4 | -94.54 Million EUR | 0.0% |
| 2016 FY | -94.54 Million EUR | -143.5% |
| 2015 FY | -38.82 Million EUR | 0.78% |
| 2015 Q2 | -29.39 Million EUR | 0.0% |
| 2015 Q4 | -38.82 Million EUR | 0.0% |
| 2014 Q1 | -28.07 Million EUR | 10.51% |
| 2014 Q4 | -39.13 Million EUR | 0.0% |
| 2014 Q2 | -28.15 Million EUR | -0.29% |
| 2014 FY | -39.13 Million EUR | -24.73% |
| 2013 Q4 | -31.37 Million EUR | 0.0% |
| 2013 FY | -31.37 Million EUR | -72.68% |
| 2012 FY | -18.16 Million EUR | 35.85% |
| 2011 FY | -28.32 Million EUR | -169.71% |
| 2010 FY | -10.5 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nicox S.A. | 13.89 Million EUR | 13318.941% |
| European Medical Solutions | 13.93 Million EUR | 13283.832% |
| FERMENTALG | 4.19 Million EUR | 43902.52% |
| BioSenic S.A. | 28.04 Million EUR | 6649.136% |
| Celyad Oncology SA | -6.1 Million EUR | -29998.978% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | -7213.793% |
| Onward Medical N.V. | -12.89 Million EUR | -14144.142% |
| Oxurion NV | 10.71 Million EUR | 17248.83% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | -667768.967% |
| Financière de Tubize SA | 78.62 Million EUR | 2435.944% |
| UCB SA | 2.17 Billion EUR | 184.366% |